Cartesian Therapeutics, Inc.
RNACdata completeness 88%12 fiscal years on fileData notes: no data for concept 'totalDebt'
Cartesian Therapeutics, Inc. earns about -38% on equity, and has bought back 77% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $85.1M1 | $110.8M1 | $26M2 | $38.3M3 | $400,0003 |
| Net income | −$25.7M4 | $35.4M4 | −$219.7M5 | −$77.4M6 | −$130.3M6 |
| Operating cash flow | −$60.4M7 | −$31.6M7 | −$51.2M8 | −$23.7M9 | −$73.9M9 |
| Capital expenditure | $1.09M10 | $1.2M10 | $206,00011 | $9.09M12 | $5.45M12 |
| Free cash flow (derived) | −$61.5M7 | −$32.8M7 | −$51.4M8 | −$32.8M9 | −$79.4M9 |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $114.1M13 | $106.4M13 | $76.9M14 | $212.6M15 | $125.1M15 |
| Diluted shares | 114.3M | 145.9M | 5.2M | 17.4M | 26.0M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$48.6 of net worth that earned you −$50.17 and generated −$30.57 of cash last year.
It earned an average -38% on equity over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is down 77% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001453687-24-000036 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001453687-25-000060 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-12-31 · accession 0001453687-26-000064 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001453687-24-000036 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001453687-25-000060 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001453687-26-000064 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001453687-24-000036 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001453687-25-000060 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001453687-26-000064 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001453687-24-000036 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001453687-25-000060 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001453687-26-000064 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001453687-24-000036 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001453687-25-000060 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001453687-26-000064 (CashAndCashEquivalentsAtCarryingValue)